Most people with hepatitis C go untreated, despite effective drugs

by Laura Kennedy

Just 20 percent of people infected with the hepatitis C virus (HCV) begin the recommended treatment regimen and less than 5 percent go on to successfully overcome the virus, according to a new review in General Hospital Psychiatry. This is despite the availability of highly effective anti-viral drugs that clear hepatitis C virus in about 80 percent of patients participating in clinical trials. Major barriers to recommended care are substance abuse and depression in HCV patients.

Other barriers to treatment include patients' attitudes toward treatment, including a fear of the side effects associated with some of the anti-viral drugs and an inability or unwillingness to abstain from drugs or alcohol, which is required for successful treatment.

As many as 4 million Americans have , which is a blood-borne viral infection that is the most common cause of severe liver disease and in the United States. In the past, hepatitis C was sometimes transmitted during medical procedures such as blood transfusions but this risk has been significantly reduced. The illicit use of injection drugs is the primary source of new infections.

People who engage in high-risk behavior in their youth often don't realize they have HCV until they reach middle age and are diagnosed with end-stage liver disease, said Barry Hong, Ph.D., of Washington University School of Medicine in St. Louis, a coauthor of the review. Recently, the Centers for Disease Control and Prevention recommended that all be screened for HCV.

"Screening patients with psychiatric and substance use disorders is also a must," notes Muhamad Aly Rifai, M.D., a psychiatrist specializing in mental illness and at the Commonwealth Medical College in Pennsylvania.

The findings suggest that many of these barriers to care can be readily addressed through education or by treating patients' mental conditions before or during treatment for HCV, including the use of anti-depressants, the authors suggest.

In addition to their high risk health behaviors, many also face practical barriers to accessing treatment such as lack of transportation, good social supports, or adequate housing. The authors recommend providing a multidisciplinary treatment approach that involves social workers, physician assistants and others to provide assistance.

The review also "underscores the need for better anti-HCV regimens with fewer side effects," notes Frederick Askari, M.D., Ph.D., a hepatologist at the University of Michigan Medical Center. "Fortunately better treatments are on the horizon, with over 20 promising compounds in various stages of clinical development."

More information: North C., et al. Hepatitis c treatment and SVR: the gap between clinical trials and real-world treatment aspirations. General Hospital Psychiatry, 2012.

Related Stories

Keeping hepatitis C virus at bay after a liver transplant

date Oct 01, 2009

One of the most common reasons for needing a liver transplant is liver failure or liver cancer caused by liver cell infection with hepatitis C virus (HCV). However, in nearly all patients the new liver becomes infected with ...

New vaccine for hepatitis C virus

date Jul 28, 2011

Murdoch University researchers have begun a study to develop a new and innovative vaccine for the hepatitis C virus (HCV).

Recommended for you

Third Minnesota turkey farm hit by bird flu outbreak

date 13 hours ago

An outbreak of a bird flu strain that's deadly to poultry deepened Saturday when state and federal officials confirmed a third Minnesota turkey farm has been infected, this time in one of the state's top poultry producing ...

Nocturnal GERD tied to non-infectious rhinitis

date Mar 27, 2015

(HealthDay)—Nocturnal gastroesophageal reflux disease (GERD) appears to be a risk factor for non-infectious rhinitis (NIR), according to a study published online March 24 in Allergy.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.